CD68 and small cell lung carcinoma: Another case–control study compared surgically resected tumor specimens from long-term SCLC survivors (survival > 4 years) and SCLC patients with expected survival time (survival < 2 years), revealing higher numbers of CD14 + monocytes, FOXP3 + lymphocytes, and CD68 + macrophages in long-term survivors (LTS).